Evidence map›Paper›PMID 36762608›Full record

ArticleJournal of biological rhythms2023

Diurnal Changes in Capecitabine Clock-Controlled Metabolism Enzymes Are Responsible for Its Pharmacokinetics in Male Mice.

Yasemin Kubra Akyel, Dilek Ozturk Civelek, Narin Ozturk Seyhan, Seref Gul, Isil Gazioglu, Zeliha Pala Kara, Francis Lévi, Ibrahim Halil Kavakli, Alper Okyar

Open access · hybridAbstract read
In one paragraph

Article in Journal of biological rhythms, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Yasemin Kubra AkyelDepartment of Pharmacology, Faculty of Pharmacy, Istanbul University, Istanbul, Turkey.ORCID 0000-0002-1734-8340
Dilek Ozturk CivelekDepartment of Pharmacology, Faculty of Pharmacy, Bezmialem Vakif University, Istanbul, Turkey.
Narin Ozturk SeyhanDepartment of Pharmacology, Faculty of Pharmacy, Istanbul University, Istanbul, Turkey.
Seref GulBiotechnology Division, Department of Biology, Faculty of Science, Istanbul University, Istanbul, Turkey.
Isil GaziogluDepartment of Analytical Chemistry, Faculty of Pharmacy, Bezmialem Vakif University, Istanbul, Turkey.
Zeliha Pala KaraDepartment of Pharmacology, Faculty of Pharmacy, Istanbul University, Istanbul, Turkey.
Francis LéviUPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France.
Ibrahim Halil KavakliDepartment of Molecular Biology and Genetics, Koc University, Istanbul, Turkey.ORCID 0000-0001-6624-3505
Alper OkyarDepartment of Pharmacology, Faculty of Pharmacy, Istanbul University, Istanbul, Turkey.ORCID 0000-0002-9891-5588
Istanbul University · TRBezmiâlem Vakıf Üniversitesi · TRIstanbul Medipol University · TRKoç University · TRUniversité Paris-Saclay · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The circadian timing system controls absorption, distribution, metabolism, and elimination processes of drug pharmacokinetics over a 24-h period. Exposure of target tissues to the active form of the drug and cytotoxicity display variations depending on the chronopharmacokinetics. For anticancer drugs with narrow therapeutic ranges and dose-limiting side effects, it is particularly important to know the temporal changes in pharmacokinetics. A previous study indicated that pharmacokinetic profile of capecitabine was different depending on dosing time in rat. However, it is not known how such difference is attributed with respect to diurnal rhythm. Therefore, in this study, we evaluated capecitabine-metabolizing enzymes in a diurnal rhythm-dependent manner. To this end, C57BL/6J male mice were orally treated with 500 mg/kg capecitabine at ZT1, ZT7, ZT13, or ZT19. We then determined pharmacokinetics of capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine (5'DFCR), 5'-deoxy-5-fluorouridine (5'DFUR), 5-fluorouracil (5-FU), in plasma and liver. Results revealed that plasma

Indexed as

Antimetabolites, AntineoplasticCircadian RhythmAnimalsCapecitabineFluorouracilMaleMiceMice, Inbred C57BLRatsAntimetabolites, AntineoplasticCapecitabineFluorouracilcancercapecitabinechronopharmacokineticschronotherapydiurnal rhythmsdrug metabolism

Identifiers

PMID36762608
PMCPMC10037547
OpenAlexW4319812960

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.